degarelix Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
gonadotropin-releasing-hormone (GnRH) inhibitors, peptides 4379 214766-78-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • degarelix
  • firmagon
  • degarelix acetate
FE-200486 is the acetate salt
  • Molecular weight: 1632.29
  • Formula: C82H103ClN18O16
  • CLOGP: 2.75
  • LIPINSKI: 3
  • HAC: 34
  • HDO: 17
  • TPSA: 512.87
  • ALOGS: -5.60
  • ROTB: 41

Drug dosage:

DoseUnitRoute
2.70 mg P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.74 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.68 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 18.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 24, 2008 FDA FERRING

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Other hormone antagonists and related agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Advanced Prostatic Carcinoma indication
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Osteopenia contraindication 312894000
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.99 acidic
pKa2 11.49 acidic
pKa3 12.21 acidic
pKa4 12.25 acidic
pKa5 12.82 acidic
pKa6 13.11 acidic
pKa7 13.11 acidic
pKa8 13.39 acidic
pKa9 13.47 acidic
pKa10 13.85 acidic
pKa11 9.64 Basic
pKa12 5.35 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 5925730 May 18, 2021 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 5925730 May 18, 2021 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9579359 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9579359 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9415085 April 27, 2032 METHOD OF TREATING PROSTATE CANCER
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9415085 April 27, 2032 METHOD OF TREATING PROSTATE CANCER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Gonadotropin-releasing hormone receptor GPCR ANTAGONIST Ki 8.77 IUPHAR CHEMBL

External reference:

IDSource
D08635 KEGG_DRUG
4028567 VUID
N0000178334 NUI
C1455035 UMLSCUI
441758000 SNOMEDCT_US
475230 RXNORM
4028567 VANDF
164686 MMSL
d07411 MMSL
441864003 SNOMEDCT_US
012979 NDDF
CHEMBL415606 ChEMBL_ID
I18S89P20R UNII
934246-14-7 SECONDARY_CAS_RN
8192 INN_ID
DB06699 DRUGBANK_ID
CHEBI:135961 CHEBI
5585 IUPHAR_LIGAND_ID
CHEMBL2028987 ChEMBL_ID
16136245 PUBCHEM_CID
C431566 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
FIRMAGON HUMAN PRESCRIPTION DRUG LABEL 1 55566-8303 KIT 20 mg None NDA 19 sections
FIRMAGON HUMAN PRESCRIPTION DRUG LABEL 1 55566-8403 KIT 40 mg None NDA 19 sections